CHO Pharma (ROCO:6586) EBITDA Margin %: -21,997.91% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6586 CHO Pharma Inc ROCO:6586
30 GF Score
Price NT$111.00
! 4 Warning Signs
View Full Analysis

What is CHO Pharma EBITDA Margin %?

CHO Pharma ROCO:6586 -9.39% 30 EBITDA Margin % is -21,997.91% as of Dec. 2025. GuruFocus rates ROCO:6586 with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 939 Biotechnology companies, CHO Pharma ranks worse than 95.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. CHO Pharma's EBITDA for the six months ended in Dec. 2025 was NT$-158.17 Mil. CHO Pharma's Revenue for the six months ended in Dec. 2025 was NT$0.72 Mil. Therefore, CHO Pharma's EBITDA margin for the quarter that ended in Dec. 2025 was -21,997.91%.

CHO Pharma  (ROCO:6586) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

CHO Pharma EBITDA Margin % Related Terms

CHO Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for CHO Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CHO Pharma EBITDA Margin % Chart

CHO Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,657.31 -497,070.00 0.00 -5,185.73 -18,372.40

CHO Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -8,027.45 -3,954.84 -14,711.24 -21,997.91

ROCO:6586 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, CHO Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CHO Pharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CHO Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where CHO Pharma's EBITDA Margin % falls into.


ROCO:6586
30GF Score
CHO Pharma Inc ROCO:6586
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CHO Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

CHO Pharma's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-262.909/1.431
=-18,372.40 %

CHO Pharma's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-158.165/0.719
=-21,997.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -21,997.91% mean?
CHO Pharma (ROCO:6586) has a EBITDA Margin % of -21,997.91% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CHO Pharma and its competitors. According to the industry distribution chart, CHO Pharma ranks #893 out of 939 companies in the Biotechnology industry, placing it in the top 95.1%.
Is CHO Pharma's EBITDA Margin % too high?
CHO Pharma's current EBITDA Margin % is -21,997.91%. Based on the distribution chart, CHO Pharma ranks #893 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CHO Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CHO Pharma ranks #893 out of 939 companies for EBITDA Margin %. This places CHO Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CHO Pharma and its competitors. CHO Pharma's current EBITDA Margin % is -21,997.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current EBITDA Margin % of -21,997.91%. The current EBITDA Margin % is -21,997.91%. CHO Pharma's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current EBITDA Margin % is -21,997.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CHO Pharma Business Description

Address Lane 130, Sec. 1 Academia Road, 7th Floor, Building C, No.99, Nangang, Taipei, TWN, 115202
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
30GF Score

Get the complete analysis for ROCO:6586

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$111.00
Price